The Palliative Role of Colchicine on Advanced Hilar Cholangiocarcinoma Patient with Socio-Economic Challenges: A Case Report
DOI:
https://doi.org/10.19166/med.v14i2.9556Keywords:
Colchicine, Advanced Hilar Cholangiocarcinoma, Palliative Role, Case ReportAbstract
Cholangiocarcinoma is a rare, slow-growing tumor that commonly presents beyond the point of resectability. Current guidelines recommend chemotherapy and radiotherapy for inoperable cases. However, palliative resources are not always accessible for patients with socio-economic barriers. Meanwhile, colchicine is a cost-effective drug and possesses anticancer effects. Here, we present a 53-year-old man with a 6-month history of painless jaundice, severe pruritus, recurrent fever, progressively growing abdominal mass, loss of appetite, and significant weight loss. He was incapable to perform adequate self-care and remained bedridden. Courvoisier sign was noted. Liver function tests show hyperbilirubinemia with elevated CA 19-9 level. Abdominal MRI 3T and MRCP showed hilar cholangiocarcinoma and obliteration of the hepatic vein. The patient and his family did not have health insurance and lived on a minimum income. Considered inoperable, the patient received daily colchicine 1 mg. Within four months, his symptoms have subsided, and he could perform several house chores. Bilirubin also showed a decreasing trend. In neoplastic cells, colchicine inhibits cell mitosis by perturbing tubulin formation. Being widely available, colchicine can be a palliative drug for terminally ill patients with socio-economic challenges. Although it improves patient performance status, we recommend further studies and close monitoring for the use of colchicine in advanced cholangiocarcinoma cases.
References
1. Patel T. Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189-200. https://doi.org/10.1038/nrgastro.2011.20
2. Hawley P. Barriers to Access to Palliative Care. Palliat Care. 2017;10. https://doi.org/10.1177/1178224216688887
3. Sivakumar G. Colchicine Semisynthetics: Chemotherapeutics for Cancer? Curr Med Chem. 2013;20(7):892-898. http://dx.doi.org/10.2174/0929867311320070005
4. Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. 2016 May;122(9): 1349-1469. https://doi.org/10.1002/cncr.29692
5. Lee RM, Liu Y, Gamboa AC, et al. Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment? J Surg Oncol. 2019;120(4):611-623. https://doi.org/10.1002/jso.25632
6. Suarez-Munoz MA. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol. 2013;5(7):132. https://doi.org/10.4251/wjgo.v5.i7.132
7. Aktas G, Kus T, Balkan A, Metin T, Gulsen MT, Abali H. Prognostic factors in patients with advanced extrahepatic cholangiocarcinoma: A single center experience. Medicine (Baltimore). 2019;98(8):e14556. https://doi.org/10.1097/md.0000000000014556
8. Adiyanti SS, Sosrosumihardjo R. The Role of Various Laboratory Parameters and Imaging Associated with Obstructive Jaundice in Cholangiocarcinoma. Indones J Gastroenterol Hepatol Dig Endosc. 2014;15(1):57-62. https://media.neliti.com/media/publications/65787-EN-the-role-of-various-laboratory-parameter.pdf
9. Tajiri T, Yoshida H, Mamada Y, Taniai N, Yokomuro S, Mizuguchi Y. Diagnosis and initial management of cholangiocarcinoma with obstructive jaundice. World J Gastroenterol. 2008;14(19):3000-3005. https://doi.org/10.3748/wjg.14.3000
10. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27: v28-v37. https://doi.org/10.1093/annonc/mdw324
11. Molina V, Sampson J, Ferrer J, et al. Klatskin Tumor: Diagnosis , Preoperative Evaluation and Surgical Considerations §. Cir Esp. 2015:1-9. https://doi.org/10.1016/j.ciresp.2015.07.003
12. Zhang H, Zhu J, Ke F, et al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015. https://doi.org/10.1155/2015/497942
13. Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar Cholangiocarcinoma: Expert consensus statement. Hpb. 2015;17(8):691-699. https://doi.org/10.1111/hpb.12450
14. Wu CC, Lin ZY, Kuoc CH, Chuang WL. Clinically acceptable colchicine concentrations have potential for the palliative treatment of human cholangiocarcinoma. Kaohsiung J Med Sci. 2015;31(5):229-234. https://doi.org/10.1016/j.kjms.2015.01.008
15. Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-350. https://doi.org/10.1016/j.semarthrit.2015.06.013
16. Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006;17(2):304-312. https://doi.org/10.1093/annonc/mdj072
17. Woradet S, Songserm N, Promthet S, Parkin DM. Health-related quality of life and survival of cholangiocarcinoma patients in northeastern region of Thailand. PLoS One. 2016;11(9):1-10. https://doi.org/10.1371/journal.pone.0163448
18. Link LH, Bindels AJGH, Brassé BP, Intven FA, Grouls RJE, Roos AN. Severe colchicine intoxication; always lethal?!? Netherlands J Crit Care. 2014;18(4):19-21. https://tinyurl.com/32kth6f4
19. Dinçkal Ç. Acute colchicine toxicity: A case report. Demiroğlu Bilim Univ Florence Nightingale J Med. 2019;5(3):152-154. http://dx.doi.org/10.5606/fng.btd.2019.028
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
